Miosis during L-dopa therapy.
The pupillary diameter of 11 patients with Parkinson's disease was significantly decreased four hours after ingestion of L-dopa. It is suggested that this miosis may be caused by diminished noradrenaline output at sympathetic nerve endings, or alternatively by an action on the central nervous system.
D000368:Aged; D002490:Central Nervous System / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009411:Nerve Endings / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D010781:Photography; D011680:Pupil / Q000033:anatomy & histology / Q000187:drug effects*; D013564:Sympathetic Nervous System / Q000378:metabolism
D004295:Dihydroxyphenylalanine; D009638:Norepinephrine